Ever wondered what it'd be like to run a de novo antibody campaign against 100 of the hardest targets, simultaneously, with 76% success rate, and have the complete wetlab validated results days from the project's start? We show you what that looks like, too: www.jurabio.com/mesa
JURA is launching a new target intelligence dashboard called MESA jurabio.com/mesa with a nice interactive case study from our recent TCRm campaigns. Go check it out -- we'll open to crowd-sourced targets soon. @jura.bsky.social
This constraint has shaped every aspect of how drug discovery operates: the emphasis on computational scoring, the reliance on expert intuition, the months of debate about which designs deserve the scarce resource of actual synthesis.
But prediction is valuable when verification is expensive.